New diagnostic tests — such as those that identify biomarkers to predict or detect a wide range of diseases — may lead to early diagnosis in certain patients, but they will also increase the frequency of false positives, overdiagnosis, and overtreatment in others. Former Commonwealth Fund Harkness Fellow Bjorn Hofmann and H. Gilbert Welch explain how to minimize harm in a new analysis in BMJ.